Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zemplar
Paricalcitol is a synthetic, active vitamin D analog used to treat secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on dialysis. It works by binding to vitamin D receptors, suppressing parathyroid hormone (PTH) synthesis and secretion, and regulating calcium and phosphorus metabolism. Paricalcitol offers more targeted action on the parathyroid gland compared to other vitamin D analogs, potentially reducing the risk of hypercalcemia.
Used to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
Outcome:
Increased risk of hyperphosphatemia
Mechanism:
Reduced phosphate absorption
Outcome:
Increased risk of hypercalcemia
Mechanism:
Additive effects
Outcome:
May affect absorption
Mechanism:
Unknown
Most likely new formulation: Extended-release paricalcitol (Year: 2026, 70% confidence)
Based on current clinical trial data and usage trends, there is a 90% likelihood of continued regulatory approval for paricalcitol in the treatment of secondary hyperparathyroidism.
Vitamin D Analog
Vitamin D analog